Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.

Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Payne JE, Jenkins DA, Bonnefous C, Trotter C, Wang Y, Anzola JV, Milkova EL, Hoffman TZ, Dozier SJ, Wiley BM, Saven A, Malecha JW, Davis RL, Muhammad J, Shiau AK, Noble SA, Rao TS, Smith ND, Hager JH.

Mol Cancer Ther. 2008 May;7(5):1054-65. doi: 10.1158/1535-7163.MCT-07-2347.

2.

Histone deacetylase inhibitors: the Abbott experience.

Curtin M, Glaser K.

Curr Med Chem. 2003 Nov;10(22):2373-92. Review.

PMID:
14529480
3.
4.

Histone deacetylase as a new target for cancer chemotherapy.

Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6. Review.

PMID:
11587361
5.

Non-hydroxamate histone deacetylase inhibitors.

Suzuki T, Miyata N.

Curr Med Chem. 2005;12(24):2867-80. Review.

PMID:
16305476
6.

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

Santini V, Gozzini A, Ferrari G.

Curr Drug Metab. 2007 May;8(4):383-93. Review.

PMID:
17504226
7.

Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.

Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, Aranda A.

Clin Transl Oncol. 2008 Jul;10(7):395-8. Review.

PMID:
18628067
8.

Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.

Codd R, Braich N, Liu J, Soe CZ, Pakchung AA.

Int J Biochem Cell Biol. 2009 Apr;41(4):736-9. doi: 10.1016/j.biocel.2008.05.026. Epub 2008 Aug 3. Review.

PMID:
18725319
9.

Discovery and development of SAHA as an anticancer agent.

Marks PA.

Oncogene. 2007 Feb 26;26(9):1351-6. Review.

PMID:
17322921
10.

Histone deacetylation : an attractive target for cancer therapy?

Al-Janadi A, Chandana SR, Conley BA.

Drugs R D. 2008;9(6):369-83. doi: 10.2165/0126839-200809060-00003. Review.

PMID:
18989989
11.

Development of histone deacetylase inhibitors for cancer treatment.

Marchion D, Münster P.

Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. Review.

PMID:
17428177
12.

The discovery of NVP-LAQ824: from concept to clinic.

Remiszewski SW.

Curr Med Chem. 2003 Nov;10(22):2393-402. Review.

PMID:
14529481
13.

Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.

Arts J, de Schepper S, Van Emelen K.

Curr Med Chem. 2003 Nov;10(22):2343-50. Review.

PMID:
14529477
14.
15.

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.

Frew AJ, Johnstone RW, Bolden JE.

Cancer Lett. 2009 Aug 8;280(2):125-33. doi: 10.1016/j.canlet.2009.02.042. Epub 2009 Apr 8. Review.

PMID:
19359091
16.

Histone deacetylase inhibitors: discovery and development as anticancer agents.

Marks PA, Dokmanovic M.

Expert Opin Investig Drugs. 2005 Dec;14(12):1497-511. Review.

PMID:
16307490
17.

Recent progress in the development of assays suited for histone deacetylase inhibitor screening.

Wegener D, Hildmann C, Schwienhorst A.

Mol Genet Metab. 2003 Sep-Oct;80(1-2):138-47. Review.

PMID:
14567963
18.

Targeting histone deacetylase in cancer therapy.

Lin HY, Chen CS, Lin SP, Weng JR, Chen CS.

Med Res Rev. 2006 Jul;26(4):397-413. Review.

PMID:
16450343
19.

Histone deacetylase inhibitors from microorganisms: the Astellas experience.

Masuoka Y, Shindoh N, Inamura N.

Prog Drug Res. 2008;66:335, 337-59. Review.

PMID:
18416310
20.

Supplemental Content

Support Center